ADIA · Adia Med, Inc. · Documents
$0.13
At close · Oct 19
Return incl. dividend (before tax)
Going-concern doubt
— flagged Aug 13, 2026
Substantial doubt about the company's ability to continue as a going concern.
“These factors, among others, raise substantial doubt about the ability of the Company to continue as a going concern for a reasonable period of time. The Company's continuation as a going concern for one year after the audit report is dependent upon, among other things, its ability to generate greater revenues and its ability to obtain capital from third parties. No assurance can be given that the Company will be successful in these efforts.”View the 10-Q filed Aug 13, 2026
Market Cap
$11.33M
Shares
94.40M
Volume · Oct 19
2600
Avg daily vol (3M)
13.35K
The company's filings as submitted to the SEC's EDGAR system — 10-K, 10-Q, 8-K, proxy statements and more — listed most recent first.
| Type | AI summary | Filing Date | Period | Open |
|---|---|---|---|---|
| 8-K | Adia Med, Inc. sold CEO Larry Powalisz seven membership units (7%) in Adia Labs LLC for $350,000.00 cash, with use of proceeds requiring joint written approval from independent directors Monica Sher, M.D. and Richard Edwards, D.O. | 2026-10-19 | 2026-10-13 | |
| 8-K | — | 2026-10-13 | 2026-10-09 | |
| 8-K | — | 2026-10-06 | 2026-09-30 | |
| 8-K | — | 2026-10-05 | 2026-09-28 | |
| 8-K | — | 2026-08-24 | 2026-08-19 | |
| 8-K | — | 2026-08-17 | 2026-07-10 | |
| 10-Q | — | 2026-08-13 | 2026-06-30 | |
| 10-Q | — | 2026-05-15 | 2026-03-31 | |
| 10-K | — | 2026-03-31 | 2025-12-31 |
Showing 1–9 of 9 filings